(-)-Blebbistatin: Selective Non-Muscle Myosin II Inhibitor Insights

Executive Summary: (-)-Blebbistatin is a small molecule inhibitor that selectively targets non-muscle myosin II (NM II), with an IC50 range of 0.5–5.0 μM under cell-based conditions (product_spec). Its mechanism involves binding to the myosin-ADP-phosphate complex, reversibly suppressing actin-myosin ATPase activity (internal_article). The compound is cell-permeable, insoluble in ethanol or water, but soluble in DMSO at concentrations ≥14.62 mg/mL (product_spec). (-)-Blebbistatin exhibits minimal off-target effects on other myosin isoforms, enabling precise modulation of cytoskeletal processes. APExBIO offers rigorously characterized (-)-Blebbistatin (B1387), supporting reproducible research in cell biology, mechanobiology, and disease modeling (product_spec).

Biological Rationale

Non-muscle myosin II (NM II) is an actin-activated motor protein essential for cell adhesion, migration, and cytoskeletal organization (Nature Communications 2025). NM II generates contractile force by hydrolyzing ATP during actin-myosin interactions, a process fundamental to tissue morphogenesis, wound healing, and cellular mechanotransduction. Inhibition of NM II enables precise dissection of cytoskeletal processes, cell mechanics, and the biophysical regulation of cell signaling. The ability to specifically and reversibly block NM II activity without broadly affecting other myosin isoforms is critical for attributing observed phenotypes to NM II function (internal_article).

Mechanism of Action of (-)-Blebbistatin

(-)-Blebbistatin acts by binding selectively to the myosin-ADP-phosphate complex, stabilizing this intermediate and slowing the release of inorganic phosphate. This suppresses Mg-ATPase activity and inhibits the contractile force generation by actomyosin complexes (internal_article; product_spec). The inhibition is reversible and does not covalently modify myosin. (-)-Blebbistatin displays high selectivity for NM II, with reported IC50 values of 0.5–5.0 μM for NM II, while demonstrating over 15-fold lower potency towards smooth muscle myosin II (IC50 ~80 μM) and negligible activity against myosin I, V, and X (product_spec).

Evidence & Benchmarks

• (-)-Blebbistatin inhibits NM II ATPase activity in vitro with an IC50 of 0.5–5.0 μM under physiological buffer conditions (source: product_spec).
• The compound is insoluble in water and ethanol but achieves ≥14.62 mg/mL solubility in DMSO, supporting high-concentration stock preparation (source: product_spec).
• Reversible inhibition enables temporal control in cell-based assays and animal models (source: internal_article).
• Minimal off-target inhibition is observed for myosin I, V, and X at concentrations used for NM II inhibition (source: product_spec).
• Used in zebrafish embryos to study cardia bifida, demonstrating a role in heart morphogenesis (source: internal_article).

Applications, Limits & Misconceptions

(-)-Blebbistatin is widely used to investigate cytoskeletal dynamics, actin-myosin interaction inhibition, and cell mechanics in both 2D and 3D cell culture models. It is employed in cardiac muscle contractility modulation and to study intercellular calcium wave propagation in corneal endothelial cells (product_spec). The compound’s selectivity enables targeted studies of NM II-driven processes, including cell migration and adhesion.

For extended perspectives on advanced applications, see "(-)-Blebbistatin: Advancing Cytoskeletal Dynamics Research", which details troubleshooting and reproducibility strategies. This current article builds upon those protocols by clarifying selectivity data and off-target profiles.

See also "(-)-Blebbistatin and Force-Mode Biology", which explores force-dependent gene regulation; here, we focus specifically on the benchmark selectivity and workflow integration for NM II.

Common Pitfalls or Misconceptions

• (-)-Blebbistatin does not inhibit all myosin isoforms equally; use at NM II-relevant concentrations to avoid off-target inactivity (source: product_spec).
• The compound is light-sensitive; photoinactivation or phototoxicity may occur under blue light or UV exposure (workflow_recommendation).
• It is not water- or ethanol-soluble; improper solvent choice leads to precipitation and assay variability (source: product_spec).
• Effects on cardiac or smooth muscle tissues require higher concentrations; misapplication at low doses may yield false negatives for these isoforms (source: product_spec).
• Reversibility is dose- and time-dependent; incomplete washout can cause residual inhibition (workflow_recommendation).

Workflow Integration & Parameters

Protocol Parameters

• enzyme inhibition assay | IC50 = 0.5–5.0 μM | NM II ATPase inhibition | For selective inhibition in live cells | product_spec
• stock solution prep | 14.62 mg/mL in DMSO | For storage and dilution | Ensures maximal solubility and stability | product_spec
• cell-based migration assay | 5 μM working concentration | NM II-specific effects | Avoids off-target myosin inhibition | product_spec
• zebrafish embryo model | 10–50 μM in E3 buffer (with DMSO carrier) | Cardia bifida studies | Recapitulates developmental phenotypes | internal_article
• storage condition | -20°C (solid), DMSO stocks frozen | All workflows | Maintains compound stability for months | product_spec

Conclusion & Outlook

(-)-Blebbistatin is a rigorously validated, cell-permeable NM II inhibitor, enabling precise control of actin-myosin interaction inhibition in diverse cellular and developmental contexts (APExBIO). Its selectivity and reversible action set benchmarks for cytoskeletal dynamics research. Recent studies on mechanotransduction and integrin-related force sensing underscore the importance of NM II in linking mechanical forces to cell signaling (Nature Communications 2025). As protocols mature and off-target profiles are clarified, (-)-Blebbistatin will remain central to dissecting cell mechanics, modeling disease, and validating therapeutic hypotheses.